<DOC>
	<DOCNO>NCT02693522</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety recombinant human growth hormone adult growth hormone deficiency</brief_summary>
	<brief_title>Evaluation Efficacy Safety Recombinant Somatroipn Patients With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Patients age 18 Patients maximum serum growth hormone concentration le 5 ng/ml Patients successfully complete study base appropriate medical judgment expect benefit study Persons agree write participate study Persons currently treatment diagnose malignant tumor Hepatosis Renal function disorder Intracranial hypertension Proliferative diabetic retinopathy Persons carry acromegaly activity Fertile woman pregnant take appropriate contraceptive measure whose urine test positive hCG ( human Chorionic Gonadotropin ) Mental patient and/or drug addict alcoholics Patients participate drug study within last 30 day prior participate study Patients consider unfit study attend physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>